Breaking News Instant updates and real-time market news.

NVO

Novo Nordisk

$48.35

0.68 (1.43%)

, CBAY

CymaBay

$9.66

0.07 (0.73%)

04:55
01/09/19
01/09
04:55
01/09/19
04:55

EBD Group to hold a conference

Biotech Showcase 2019 Conference will be held in San Francisco on January 6-9.

NVO

Novo Nordisk

$48.35

0.68 (1.43%)

CBAY

CymaBay

$9.66

0.07 (0.73%)

BTX

BioTime

$1.14

0.065 (6.07%)

INO

Inovio

$4.75

-0.17 (-3.46%)

ANTM

Anthem

$249.32

-0.79 (-0.32%)

RHHBY

Roche

$0.00

(0.00%)

VVUS

VIVUS

$2.66

-0.055 (-2.03%)

RLMD

Relmada Therapeutics

$0.00

(0.00%)

BLUE

Bluebird Bio

$113.51

-0.14 (-0.12%)

ONCE

Spark Therapeutics

$44.51

0.44 (1.00%)

CYCC

Cyclacel Pharmaceuticals

$0.72

0.0119 (1.67%)

CASI

Casi Pharmaceuticals

$4.14

(0.00%)

CVSI

CV Sciences

$0.00

(0.00%)

APTO

Aptose Biosciences

$2.40

0.055 (2.35%)

FIXX

Homology Medicines

$25.39

0.87 (3.55%)

  • 09

    Jan

  • 09

    Jan

  • 14

    Jan

  • 28

    Jan

  • 01

    Feb

  • 18

    Mar

NVO Novo Nordisk
$48.35

0.68 (1.43%)

11/19/18
JPMS
11/19/18
UPGRADE
JPMS
Overweight
Novo Nordisk upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Richard Vosser upgraded Novo Nordisk to Overweight and raised his price target for the shares to 340 kroner from 290 kroner. The analyst sees the company's growth strengthening through 2019.
11/26/18
PART
11/26/18
UPGRADE
PART
Buy
Novo Nordisk upgraded to Buy from Hold at Pareto
12/11/18
JEFF
12/11/18
INITIATION
JEFF
Hold
Novo Nordisk assumed with a Hold at Jefferies
Jefferies analyst Peter Welford assumed coverage of Novo Nordisk with a Buy rating and DKK 285 price target. The analyst is positive on the European large-cap Pharma space "as it enters a period of sustained earnings momentum." He calls Novo his least preferred stock in the group.
01/02/19
JPMS
01/02/19
NO CHANGE
JPMS
JPMorgan adds Novo Nordisk to Analyst Focus List, removes Roche
JPMorgan analyst Richard Vosser added Novo Nordisk (NVO) to his firm's European Analyst Focus List while removing Roche (RHHBY).
CBAY CymaBay
$9.66

0.07 (0.73%)

10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
06/28/18
RAJA
06/28/18
INITIATION
Target $20
RAJA
Outperform
CymaBay initiated with an Outperform at Raymond James
Raymond James analyst Steven Seedhouse initiated CymaBay with an Outperform and $20 price target.
11/14/18
PIPR
11/14/18
NO CHANGE
Target $30
PIPR
Overweight
CymaBay data show superior efficacy to Intercept's, says Piper Jaffray
The additional detail provided by CymaBay (CBAY) yesterday via the 52-week analysis of seladelpar in 34 patients "was indeed solid highlighting a superior efficacy and safety profile" relative to Intercept's (ICPT) Ocaliva, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. The data suggest that the ongoing Phase III Enhance study is highly likely to be successful, contends the analyst. He points out that that despite the "clean dataset," some are poking at a numerical increase in bilirubin levels in the 10mg arm. The analyst, however, believes this is clinically insignificant. Van Buren continues to recommend that investors purchase CymaBay shares, believing they are undervalued on the primary biliary cholangitis program alone. He keeps an Overweight rating on the name with a $30 price target.
08/09/18
PIPR
08/09/18
NO CHANGE
Target $30
PIPR
Overweight
CymaBay price target raised to $30 from $16 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren raised his price target on CymaBay to $30 and kept his Overweight rating, saying he expects the company's cinical progress and additional updates in PBC and NASH to drive its share price higher over the next 12-18 months. The analyst expects the PBC phase 2 data on seladelpar expected in Q4 to be "confirmartory", de-risking the subsequent phase 3 trial. He adds that the phase 2b proof of concept NASH study will hopefully show "clinically meaningful effects based on the preclinical data and differentiated mechanism of action".
BTX BioTime
$1.14

0.065 (6.07%)

02/02/18
LSCM
02/02/18
INITIATION
Target $8
LSCM
Buy
BioTime initiated with a Buy at Lake Street
Lake Street analyst Bruce Jackson started BioTime with a Buy rating and $8 price target. The company may appear complex given its interdependent corporate structure, but there is reward for investors who can recognize the value creation underway at both BioTime and its minority investments, Jackson tells investors in a research note.
12/10/18
OPCO
12/10/18
INITIATION
Target $3.5
OPCO
Outperform
BioTime initiated with an Outperform at Oppenheimer
Oppenheimer analyst Kevin DeGeeter started BioTime with an Outperform rating and $3.50 price target. New management is transforming BioTime from a holding company of multiple technology platforms to a product development company "committed to allocating necessary resources to the most promising drug," OpRegen for the treatment of dry age-related macular degeneration, DeGeeter tells investors in a research note. He expects OpRegen to have peak end-market revenue of $1.3B.
INO Inovio
$4.75

-0.17 (-3.46%)

06/29/18
06/29/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Construction Partners (ROAD) initiated with an Outperform at Imperial Capital. 2. Inovio (INO) assumed with an Overweight at Piper Jaffray. 3. GATX (GATX) initiated with a Buy at Mizuho. 4. Schneider National (SNDR) initiated with a Hold at Stifel. 5. Eloxx Pharmaceuticals (ELOX) initiated with a Buy at Canaccord. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/26/18
PIPR
09/26/18
NO CHANGE
Target $12
PIPR
Overweight
Piper remains buyer of Inovio after management meetings
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on shares of Inovio Pharmaceuticals with a $12 price target following a day of investor meetings with management. The analyst looks to 2019 efficacy updates for MEDI0457 and INO-5401 in combination with PD-(L)1 in head and neck, bladder cancer, and glioblastoma as validating for the Aspire platform. He continue to like the stock's set-up and remain buyers of the shares.
10/02/18
STFL
10/02/18
INITIATION
Target $8
STFL
Buy
Inovio resumed with a Buy at Stifel
Stifel analyst Stephen Willey resumed coverage of Inovio with a Buy rating and $8 price target, citing his favorable view of the clinical risk underlying the ongoing Phase 3 VGX-3100 development program in patients with HPV+ cervical HSIL. He sees the company's earlier-stage immuno-oncology development efforts and externally-funded infectious diseases programs as additional sources of longer-term upside, Willey added.
06/29/18
PIPR
06/29/18
INITIATION
Target $12
PIPR
Overweight
Inovio assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond assumed coverage of Inovio Pharmaceuticals with an Overweight rating and $12 price target. The stock is "poised for upside" as investors are assigning little value to key programs like VGX-3100, in Phase 3 for the treatment of cervical dysplasia, and INO-5410, in Phase 1/2 for bladder cancer, Raymond tells investors in a research note. He views Inovio's immunotherapy platform as differentiated with a number of key proof of concept data points in coming quarters. The analyst would be a buyer of the stock to levels approaching $12.
ANTM Anthem
$249.32

-0.79 (-0.32%)

12/04/18
CANT
12/04/18
NO CHANGE
Target $330
CANT
Overweight
Anthem price target raised to $330 from $305 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper raised his price target for Anthem to $330 after management said in investor meetings that it will use $3.2B from its pharmacy benefit manager savings beginning in 2020 and 2021 to drive membership growth in subsequent years. Accordingly, the analyst increased his top-line growth assumptions. He expects membership and revenue to grow faster without sacrificing margins and keeps an Overweight rating on Anthem.
01/03/19
EVER
01/03/19
UPGRADE
EVER
Outperform
Anthem upgraded to Outperform from In Line at Evercore ISI
01/03/19
WELS
01/03/19
NO CHANGE
Target $200
WELS
Market Perform
Cigna price target lowered to $200 from $221 at Wells Fargo
Wells Fargo analyst Peter Costa believes Anthem (ANTM) and Cigna (CI) may be spending much time in court fighting each other in 2019 and sees more risk for the latter than Anthem, since even if Cigna wins the first case it would have risk of losing the second where the sought damages against it are greater. Hence, it is possible that Cigna could agree to settle both cases for limited gains, he contends. Given the timing and Cigna's weakened balance sheet post the Express Scripts (ESRX) merger and plans to use Express Scripts' cash flow to reduce debt, Costa lowered his price target for Cigna to $200 from $221 and reiterated a Market Perform rating on the shares.
01/03/19
EVER
01/03/19
UPGRADE
EVER
Outperform
Anthem upgraded to Outperform on elevated growth at Evercore ISI
As previously reported, Evercore ISI upgraded Anthem to Outperform from In Line. Analyst Ross Muken expects Anthem to have elevated growth into 2020 and beyond from the PBM launch, with potential earnings upside outweighing any transaction delays. The analyst also expects increased visibility into services and vertical integration strategies at the March investor day.
RHHBY Roche
$0.00

(0.00%)

12/20/18
PIPR
12/20/18
NO CHANGE
Target $400
PIPR
Overweight
Survey shows 'solid fundamentals' for Biogen MS franchise, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Biogen (BIIB) with a $400 price target after surveying 100 neurologists. The survey feedback shows "solid fundamentals" for the company's multiple sclerosis portfolio, Raymond tells investors in a research note. He admits, however, that many investors are preoccupied with Tecfidera's intellectual property situation. Nonetheless, neurologists reported meaningful share gains for Tecfidera and Tysabri this quarter, says the analyst. Raymond believes worries over the impact to Biogen's multiple sclerosis franchise from Roche's (RHHBY) Ocrevus launch "may be behind us."
12/18/18
BERN
12/18/18
NO CHANGE
Target $288
BERN
Market Perform
Biogen drops after Bernstein sees potential downside of $100 on Q1 risks
Bernstein analyst Aaron Gal earlier today lowered his price target for Biogen (BIIB) to $288 from $341 while keeping a Market Perform rating on the shares. The Biogen "debate" revolves primarily around three elements: the durability of the existing franchises, the value of the company's Alzheimer's opportunity, and the potential of the pipeline to generate new drugs, Gal wrote in a research note. He believes the stock's current risk/reward balance "captures these dynamics." In Q1 of 2019, however, Biogen is facing "two significant risks," says the analyst. These are the inter partes review institution decision on its biggest drug, Tecfidera, and futility analyses of amyloid beta drugs - Roche's (RHHBY) crenezumab and potentially Biogen's own aducanumab, according to Gal. The analyst views Biogen's near-term risk/reward as "sharply negative." If a review of Tecfidera is instituted and one of the amyloid beta trials is stopped for futility, the stock "can easily" trade $100 per share lower, Gal believes. Even if one of these events goes against the company, the analyst thinks the Biogen can drop $30-$80 per share. On the other hand, passing both risks will likely only have "moderate upside" of around $30 per share as "both are assumed to be positive in sell-side consensus," Gal writes. He keeps a Market Perform rating on Biogen, which is down 7%, or $21.45, to $291.66 in afternoon trading.
12/17/18
PIPR
12/17/18
NO CHANGE
PIPR
Proteostasis deal with Genentech strenghtens balance sheet, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $14 price target on Proteostasis (PTI), noting the company announced an agreement with Roche's (RHHBY) Genentech to license small molecule modulators of an undisclosed target that lie outside of Cystic Fibrosis, which makes the company eligible for $100M in upfront and milestone payments plus royalties. Tenthoff sees this deal strengthening Proteostasis' balance sheet. Additionally, Tenthoff is optimistic on Proteostasis' TripleRx combo, and expects full Phase I TripleRx data in Q1 of 2019. Longer term, the analyst anticipates TripleRx approval in 2021, with global sales of $2.0B by 2026.
VVUS VIVUS
$2.66

-0.055 (-2.03%)

RLMD Relmada Therapeutics
$0.00

(0.00%)

BLUE Bluebird Bio
$113.51

-0.14 (-0.12%)

12/06/18
12/06/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Facebook (FB) downgraded to Hold from Buy at Stifel with analyst Scott Devitt saying Facebook has made too many enemies, including politicians, regulators, technology leaders, consumers, and employees, to not experience "long-term negative ramifications on its business." 2. Conatus (CNAT) downgraded to Hold from Buy at Stifel with analyst Stephen Willey saying the Encore-PH trial missed its pre-specified primary endpoint but post-hoc analyses demonstrated a trend towards statistically significant/emricasan-mediated improvements in patients with compensated cirrhosis and elevated baseline hepatic venous pressure gradient values. 3. BHP Billiton (BHP) downgraded to Neutral from Overweight at JPMorgan with analyst Lyndon Fagan saying the stock has outperformed Rio Tinto (RIO) by 10% year-to-date, and is now trading "within range of our valuation." 4. Toll Brothers (TOL) downgraded to Sector Perform from Outperform at RBC Capital with analyst Michael Dahl citing a "sharper than expected weakness in orders and likelihood of further near-term declines," with softer margin assumptions attributed to a weaker outlook for orders. 5. Bluebird Bio (BLUE) downgraded to Neutral from Overweight at Piper Jaffray with analyst Tyler Van Buren saying the company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/03/18
ADAM
12/03/18
NO CHANGE
ADAM
Canaccord has positive expectations for Bluebird after bb 21217 data released
Canaccord analyst John Newman maintained a Buy rating and $250 price target on Bluebird Bio, after the company recently released bb 21217 data. Newman has continued positive expectations for the active programs, and for bb2121's clinical progression. He added that "given the previous bb2121 dose response data, we continue to expect strong response data from the ongoing Phase 2 KarMMa trial, the ongoing Phase 1 CRB-401 trial in RRMM, and future Phase 3 trial." The analyst also noted that Bluebird reported cash and marketable securities of ~$2B, which he believes should be able to fund the company to profitability.
12/19/18
RAJA
12/19/18
INITIATION
Target $165
RAJA
Strong Buy
Bluebird Bio initiated with a Strong Buy at Raymond James
Raymond James initiated Bluebird Bio with a Strong Buy and $165 price target.
12/06/18
PIPR
12/06/18
DOWNGRADE
Target $120
PIPR
Neutral
Bluebird Bio downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren downgraded Bluebird Bio to Neutral and cut his price target for the shares to $120 from $240. The stock closed Tuesday down $2.85 to $113.65. The company is "incredibly innovative" company and bb2121 and LentiGlobin are essentially curing some patients, but the benefits "are not without serious risks," Van Buren tells investors in a research note. And while these are risks worth taking for octorefractory multiple myeloma patients with just days to live, the proposition for beta thalassemia and sickle cell patients "is much more difficult," says the analyst. Further, Van Buren believes that as LentiGlobin launches next year, the "exuberance and hope" of clinical development will soon transition to "high expectations for commercial performance." Key opinion leaders agree that broad uptake of LentiGlobin will be challenging, admits the analyst. He lowered his estimates for LentiGlobin and downgraded Bluebird Bio to Neutral.
ONCE Spark Therapeutics
$44.51

0.44 (1.00%)

11/15/18
HCWC
11/15/18
NO CHANGE
Target $48
HCWC
Buy
uniQure's AMT-061 'living up to high expectations,' says H.C. Wainwright
uniQure (QURE) has provided investors with "a compelling glimpse at what the future hold for Hemophilia B patients" after issuing an update on its AMT-061 dose confirmation study, according to H.C. Wainwright analyst Debjit Chattopadhyay. The mean Factor IX activity at six weeks was 31%, which is on par with Spark Therapeutics' (ONCE) SPK-9001, said Chattopadhyay. The analyst, who thinks AMT-061 is "living up to high expectations" and views it being positioned as "not only the best-in-class one-and-done solution, but also, the first to market," keeps a Buy rating and $48 price target on uniQure shares.
11/16/18
FBCO
11/16/18
UPGRADE
Target $44
FBCO
Neutral
Spark Therapeutics upgraded to Neutral from Underperform at Credit Suisse
Credit Suisse analyst Martin Auster upgraded Spark Therapeutics (ONCE) to Neutral from Underperform but lowered his price target to $44 from $48. In a research note to investors, Auster says that with uniQure's (QURE) update validating AMT-061, its second generation hemophilia B gene therapy construct incorporating the Padua variant, and Freeline's initial data disclosed in ASH abstracts, he sees a more competitive landscape in hemophilia B gene therapy, and lowered his market share assumptions for SPK-9001 to reflect this new dynamic.However, Auster says Spark has been under significant pressure since providing an update on its hemophilia A, and believes most of the value for that program has already been discounted in the share price. Though there is limited visibility in the near-term, he sees optionality going forward within the Pompe program and/or a possible reemergence of the hem A platform ~mid-2019 from either an improved profile for SPK-8011 with prophy steroids or encouraging early data from Spark's second compound SPK-8016.
11/16/18
11/16/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst James Faucette saying he thinks consensus estimates now imply a more realistic scenario for QCT margins and that lowered expectations on a resolution with Apple (AAPL) gives room for the stock to react positively should legal proceedings trigger a settlement. 2. Spark Therapeutics (ONCE) upgraded to Neutral from Underperform at Credit Suisse with analyst Martin Auster saying with uniQure's (QURE) update validating AMT-061, its second generation hemophilia B gene therapy construct incorporating the Padua variant, and Freeline's initial data disclosed in ASH abstracts, he sees a more competitive landscape in hemophilia B gene therapy, and lowered his market share assumptions for SPK-9001 to reflect this new dynamic. 3. Armstrong Flooring (AFI) upgraded to Buy from Hold at Gabelli with analsyt Alvaro Lacayo saying the sale of the wood business is a transformative deal and removes two underperforming segments that have been under increased pressure from private label competition. 4. DSW (DSW) upgraded to Neutral from Negative at Susquehanna. 5. PG&E (PCG) and Edison International (EIX) were upgraded to Buy from Neutral at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/16/18
FBCO
11/16/18
UPGRADE
FBCO
Neutral
Spark Therapeutics upgraded to Neutral from Underperform at Credit Suisse
CYCC Cyclacel Pharmaceuticals
$0.72

0.0119 (1.67%)

09/05/18
ROTH
09/05/18
INITIATION
Target $8
ROTH
Buy
Cyclacel Pharmaceuticals initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Cyclacel Pharmaceuticals with a Buy rating and $8 price target. The analyst believes that Cyclacel, its clinical CDK inhibitor CYC065, and its indirect target MCL-1 should all go into the watchlist of anyone interested in CLL.
09/07/18
LTCO
09/07/18
INITIATION
Target $6.25
LTCO
Buy
Cyclacel Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started Cyclacel Pharmaceuticals with a Buy rating and $6.25 price target. The analyst believes CYC065 has shown promise in Mcl-1 regulation.
CASI Casi Pharmaceuticals
$4.14

(0.00%)

01/16/18
HCWC
01/16/18
NO CHANGE
Target $4.5
HCWC
Buy
Casi Pharmaceuticals price target raised to $4.50 from $2 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Casi Pharmaceuticals to $4.50 saying changes to Chinese regulations could lead to approvals in 2018. Under China's new regulations, if a drug is already marketed overseas, it could directly apply for conditional approval without the need for a clinical study, Ramakanth tells investors in a research note. He notes that management confirmed to him that all three of the company's licensed oncology products, Evomela, Marqibo, and Zevalin, fall under this category. The analyst keeps a Buy rating on Casi.
CVSI CV Sciences
$0.00

(0.00%)

11/07/18
ADAM
11/07/18
NO CHANGE
ADAM
Midterms broadly positive for U.S. cannabis industry, says Canaccord
Canaccord analyst Bobby Burleson says that as expected, yesterday's midterms delivered several wins for the U.S. cannabis industry, including the passage of three state ballot measures on legalization, key gubernatorial victories by pro-cannabis candidates, and the retaking of the House by Democrats. The analyst views these results as broadly positive for the U.S. cannabis industry. Publicly traded companies in the space include Aurora Cannabis (ACB), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
09/20/18
STFL
09/20/18
NO CHANGE
STFL
Top 22 Canadian cannabis stocks up 127% since Constellation pact, says Stifel
Yesterday's significant outperformance for Canadian cannabis stocks, led by Tilray (TLRY), at one point pushed the total market capitalization for Canadian Licensed Producers above $C80B, before they closed with a combined market cap of C$73B, calculates Stifel analyst Christopher Growe. Since August 15, when Constellation Brands (STZ) announced a pact to invest C$5B into Canopy Growth (CGC), the top 22 Canadian cannabis stocks are up 127% in stock price, noted Growe. A $C73B market cap in relation to what he estimates to be an addressable Canadian market of C$10B is "difficult to fathom," so valuations require global opportunities to be realized, added Growe, who said he questions the pace of development and degree of advantage for these companies. Companies in the cannabis space that can be traded in the U.S. include Aurora Cannabis (ACBFF), CV Sciences (CVSI), Canopy Growth, Cronos Group (CRON) and Tilray.
10/17/18
MSCO
10/17/18
NO CHANGE
MSCO
Morgan Stanley says pot legalization could pose risk to Canadian auto insurers
Morgan Stanley analyst Kai Pan noted that academic studies do not agree on the potential impact on car accidents from legalized recreational use of marijuana, but he still believes Canada's legalization could pose a risk to Canadian auto insurers. IFC, the largest auto insurer in Canada, is not immune to this challenge but given its long-term outperformance versus peers and strong claims management, Pan thinks the company should be better positioned in addressing this challenge, he tells investors. Publicly traded companies in the cannabis space include Aurora Cannabis (ACBFF), CV Sciences (CVSI), CannTrust Holdings (CNTTF), Canopy Growth (CGC), Cronos Group (CRON), General Cannabis (CANN), India Globalization Capital (IGC) and Tilray (TLRY).
APTO Aptose Biosciences
$2.40

0.055 (2.35%)

06/29/18
HCWC
06/29/18
NO CHANGE
Target $8.5
HCWC
Buy
Aptose Biosciences target raised to $8.50 at H.C. Wainwright after hold lifted
H.C. Wainwright analyst Joseph Pantginis raised his price target on Aptose Biosciences to $8.50 from $6.00 after the FDA lifted the clinical hold on APTO-253, stating that he believes the company has two potentially first-in and best-in class drugs for the treatment of hematological malignancies with that one and CG-806. He maintains a Buy rating on Aptose Biosciences shares, which are up 17c, or 4.5%, to $3.95 in early trading.
06/15/18
HCWC
06/15/18
NO CHANGE
Target $6
HCWC
Buy
Aptose presentation at EHA strengthens profile for CG-806, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis said the presentation made today at the EHA meeting by Aptose Biosciences strengthens the profile for CG-806 and his confidence is higher that the preclinical database generated should translate to meaningful clinical responses in AML and lymphoma patients. He maintains a Buy rating and $6 price target on Aptose shares.
10/10/18
HCWC
10/10/18
NO CHANGE
Target $8.5
HCWC
Buy
Aptose Biosciences recent selloff unwarranted, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis attributes the recent weakness in shares of Aptose Biosciences to the pushout of the CG-806 investigational new drug application from year-end 2018 to early 2019 as well as the planned addition of a healthy volunteer pharmacokinetic study for the AML arm of the planned IND. The analyst believes some investors have wrongly associated this with potential issues regarding the ongoing toxicology studies. He views the pullback as warranted and thinks current share levels of Aptose represent a "compelling opportunity to participate in a ground floor opportunity of two potential transformational drugs." Pantginis reiterates a Buy rating on the shares with an $8.50 price target.
11/16/18
RILY
11/16/18
INITIATION
Target $5
RILY
Buy
Aptose Biosciences initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Dylan Dupuis started Aptose Biosciences with a Buy rating and $5 price target citing the potential of the company's "two unique first-in-class "drugs entering the clinic to treat different kinds of leukemia. The analyst sees potential for an accelerated path to market for CG-806 to treat acute myelogenous leukemia based on "strong preclinical efficacy and safety data."
FIXX Homology Medicines
$25.39

0.87 (3.55%)

04/24/18
BTIG
04/24/18
INITIATION
Target $35
BTIG
Buy
Homology Medicines initiated with a Buy at BTIG
BTIG analyst Robert Hazlett initiated Homology Medicines with a Buy rating and a price target of $35, saying the company is "in the process of rapidly advancing a more effective and more efficient, next-generation technology" within the gene therapy/gene editing landscape. Hazlett points to the company's "recent discovery of hematopoietic stem cell-derived adeno-associated virus vector which possess a cluster of important differentiating characteristics that appear highly amenable to both gene therapy and gene editing", concluding that Homology Medicines operations would be attractive to a potential suitor.
09/07/18
RILY
09/07/18
INITIATION
Target $18.5
RILY
Neutral
Homology Medicines initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Homology Medicines with a Neutral rating and $18.50 price target.
01/07/19
01/07/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Pivotal Research. 2. Dell Technologies (DELL) initiated with a Buy at Goldman Sachs. 3. Tencent Music (TME) initiated with an Overweight at KeyBanc, a Buy at Goldman Sachs, and a Hold at Stifel. 4. Huntington Ingalls (HII) initiated with a Neutral at JPMorgan. 5. Homology Medicines (FIXX) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
01/07/19
ADAM
01/07/19
INITIATION
Target $37
ADAM
Buy
Homology Medicines initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated Homology Medicines with a Buy rating as she views its gene editing platform tool as the most promising for in vivo therapy, overcoming the challenges with safety and efficacy that have limited nuclease-based editing platforms. The analyst expects its KU gene-transfer program updates to be a primary value driver in 2019. Gilson has a $37 price target on Homology Medicines shares.

TODAY'S FREE FLY STORIES

SFLY

Shutterfly

$42.49

-0.46 (-1.07%)

16:05
04/25/19
04/25
16:05
04/25/19
16:05
Earnings
Shutterfly raises 2019 EPS outlook to 61c-$1.11 from 55c-$1.06 »

Consensus 74c. Affirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

SBBP

Strongbridge Biopharma

$4.73

0.06 (1.28%)

16:05
04/25/19
04/25
16:05
04/25/19
16:05
Hot Stocks
Strongbridge Biopharma presents new secondary endpoint data on SONICS trial »

Strongbridge Biopharma…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

CVTI

Covenant Transportation

$19.74

-0.925 (-4.48%)

16:05
04/25/19
04/25
16:05
04/25/19
16:05
Earnings
Covenant Transportation reports Q1 EPS 24c, consensus 21c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 08

    May

  • 21

    May

  • 13

    Nov

CDNA

CareDx

$25.97

-0.48 (-1.81%)

16:04
04/25/19
04/25
16:04
04/25/19
16:04
Hot Stocks
CareDx to acquire OTTR Complete Transplant Management »

CareDx announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 28

    May

TMUS

T-Mobile

$72.85

-0.5 (-0.68%)

16:04
04/25/19
04/25
16:04
04/25/19
16:04
Earnings
T-Mobile reports Q1 EPS $1.06, consensus 91c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

SFLY

Shutterfly

$42.43

-0.52 (-1.21%)

16:03
04/25/19
04/25
16:03
04/25/19
16:03
Earnings
Shutterfly reports Q1 EPS ($2.47), consensus ($2.54) »

Report Q1 revenue $325M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

POWI

Power Integrations

$78.09

-1.95 (-2.44%)

16:03
04/25/19
04/25
16:03
04/25/19
16:03
Earnings
Power Integrations sees Q2 revenue $97M-$103M, consensus $97.38M »

Sees Q2 gross margin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    May

  • 22

    May

INTC

Intel

$57.60

-1.12 (-1.91%)

16:03
04/25/19
04/25
16:03
04/25/19
16:03
Earnings
Intel reports Q1 adjusted EPS 89c, consensus 87c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 16

    May

  • 03

    Jun

ALK

Alaska Air

$59.22

-1.59 (-2.61%)

16:03
04/25/19
04/25
16:03
04/25/19
16:03
Hot Stocks
Alaska Air reports Q1 EPS ex-items 17c, consensus 12c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 21

    May

OMCL

Omnicell

$78.19

0.67 (0.86%)

16:03
04/25/19
04/25
16:03
04/25/19
16:03
Earnings
Omnicell sees FY19 adjusted EPS $2.62-$2.82, consensus $2.51 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 28

    May

  • 30

    May

WM

Waste Management

$105.56

-0.56 (-0.53%)

16:03
04/25/19
04/25
16:03
04/25/19
16:03
Syndicate
Breaking Syndicate news story on Waste Management »

Waste Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 05

    May

  • 14

    May

  • 30

    May

POWI

Power Integrations

$78.20

-1.84 (-2.30%)

16:02
04/25/19
04/25
16:02
04/25/19
16:02
Earnings
Power Integrations reports Q1 EPS 41c, consensus 41c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 06

    May

  • 22

    May

ATRC

AtriCure

$28.09

0.11 (0.39%)

16:02
04/25/19
04/25
16:02
04/25/19
16:02
Earnings
AtriCure raises FY19 revenue view to $222M-$228M from $220M-$228M 

Consensus $225.84M.

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 22

    May

OMCL

Omnicell

$78.19

0.67 (0.86%)

16:02
04/25/19
04/25
16:02
04/25/19
16:02
Earnings
Omnicell sees Q2 adjusted EPS 61c-66c, consensus 56c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 28

    May

  • 30

    May

AMZN

Amazon.com

$1,911.92

11.2 (0.59%)

16:02
04/25/19
04/25
16:02
04/25/19
16:02
Earnings
Amazon.com sees Q2 revenue $59.5B-$63.5B, consensus $62.37B »

Net sales are expected to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

ATRC

AtriCure

$28.09

0.11 (0.39%)

16:01
04/25/19
04/25
16:01
04/25/19
16:01
Earnings
AtriCure reports Q1 adjusted EPS (20c), consensus (24c) »

Reports Q1 revenue $54M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

  • 22

    May

OMCL

Omnicell

$78.19

0.67 (0.86%)

16:01
04/25/19
04/25
16:01
04/25/19
16:01
Earnings
Omnicell reports Q1 adjusted EPS 61c, consensus 41c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 14

    May

  • 28

    May

  • 30

    May

AMZN

Amazon.com

$1,912.33

11.61 (0.61%)

16:01
04/25/19
04/25
16:01
04/25/19
16:01
Earnings
Amazon.com reports Q1 EPS $7.09, consensus $4.72 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 10

    May

  • 22

    May

  • 03

    Jun

CLF

Cleveland-Cliffs

$9.76

0.24 (2.52%)

16:01
04/25/19
04/25
16:01
04/25/19
16:01
Recommendations
Cleveland-Cliffs analyst commentary  »

Cleveland-Cliffs price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

INTU

Intuit

$264.14

0.22 (0.08%)

16:00
04/25/19
04/25
16:00
04/25/19
16:00
Hot Stocks
Intuit says TurboTax Online units rose 7% season-to-date through April 20 »

Intuit Inc. released the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YUMA

Yuma Energy

$0.53

0.253 (92.00%)

15:58
04/25/19
04/25
15:58
04/25/19
15:58
Hot Stocks
Yuma says unaware of material change to account for increased market activity »

Yuma Energy announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALXN

Alexion

$135.00

4.88 (3.75%)

15:58
04/25/19
04/25
15:58
04/25/19
15:58
Recommendations
Alexion analyst commentary at Piper Jaffray »

Piper remains buyer of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 04

    May

  • 06

    May

  • 14

    May

  • 28

    Jun

CAR

Avis Budget

$35.87

-0.82 (-2.23%)

15:55
04/25/19
04/25
15:55
04/25/19
15:55
Options
Avis Budget put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 22

    May

AGCO

Agco

$69.70

-1.9 (-2.65%)

15:50
04/25/19
04/25
15:50
04/25/19
15:50
Hot Stocks
Agco raises quarterly dividend to 16c per share from 15c »

Agco announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 05

    Jun

  • 24

    Jun

  • 25

    Jun

  • 26

    Jun

BHC

Bausch Health

$23.82

0.8 (3.48%)

15:45
04/25/19
04/25
15:45
04/25/19
15:45
Recommendations
Bausch Health analyst commentary at Wells Fargo »

Bausch Health pipeline,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    May

  • 06

    May

  • 06

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.